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care admittance, Charlson co-morbidity score, state of residence, and gender all
were significant predictors of AD medication use (p  0.0001 for all variables).
Racial/ethnic disparities were observed with respect to exposure to a ChEI or me-
mantine between Non-Hispanic Whites and Hispanics (in favor of Hispanics) in
California (p  0.002) and Florida (p  0.0001), between Non-Hispanic Whites and
Non-Hispanic Others (in favor of Non-Hispanics Others) across all states, between
Non-Hispanic Blacks andNon-Hispanic Others (in favor of Non-Hispanic Others) in
California (p  0.0001) and New York (p  0.0001), and between Hispanics and
Non-Hispanic Others (in favor of Non-Hispanic Others) in California (p  0.001),
Florida (p  0.013), and New York (p  0.0001). CONCLUSIONS: Disparities in AD
medication use among minority-to-minority populations are just as prevalent, if
not higher, than minority-white disparities. Furthermore, geographical location
was important predictor of health disparities.
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OBJECTIVES: Epilepsy has been the focus of several primary care programs across
LatinAmerica region due to its high prevalence and related burden. Hospitalization
could be used as an indicator for frequency ofmore severe cases with uncontrolled
and frequent seizures. Thus, hospital admission trends could be instrumental to
understanding treatment gaps and support decision making. Our objective was to
evaluate hospital admission trend by Epilepsy in three Latin America Countries.
METHODS: Hospitalization data were extracted from Public Healthcare Databases
from Brazil, Chile and Mexico covering 2001-2008. Country and age-specific hospi-
tal admission frequencies due to Epilepsy (ICD G40) in people 14 years-old were
calculated. Three age range categories were created: 15-29; 30-44; 45-59 and 60.
We built general estimating equation models with Poisson distributions to evalu-
ate hospital admissions time trends. Further, the differences between the age
ranges were also estimated. RESULTS:Means of annual hospitalization rates were
similar in Brazil and Chile (2.63 and 2.79, respectively) but comparatively low in
Mexico (0.39). The three countries showed different in-hospital patterns over time.
Brazil had a downward tendency with an annual ratio of 0.982 (p0.001) and Chile
a relatively flat one (pNS). On the other hand, Mexico presented an upward trend,
with an annual ratio of 1.043 (p0.001). Mean hospitalization rates were higher in
older age categories in Brazil and Chile and the younger ones in Mexico. The age
categories were following the trends showed by their respective countries in the
overall analysis. CONCLUSIONS: Despite having qualitatively similar assistance
programs across the region, the countries showed different rates and patterns of
hospitalization due to Epilepsy. Direct comparison between countries should be
examined cautiously due to important differences in their health care systems and
data collection process.
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OBJECTIVES: To compare short and long-term all cause health care resource utili-
zation among newly diagnosed multiple sclerosis (MS) patients enrolled in Man-
aged Medicaid or Commercial health plans. METHODS: We used the I3 InVision
Data Mart to identify continuously enrolled patients 18 years of age with at least
two ICD-9 codes for multiples sclerosis (340.xx) between the dates of June 1, 2006
and March 31, 2010. Baseline patient characteristics as well as thirty-day and 24
month all cause health care resource utilization and costs were assessed using
Analysis of Variance (ANOVA) for continuous variables and Chi-squared statistics
for continuous variables.RESULTS:Medicaid beneficiariesweremore likely to have
more psycho-social limitations (23.5%; p 0.0001) than their counterparts insured
through commercial plans. Within the first 30 days of diagnosis, Medicaid HMO
beneficiaries were more likely to be hospitalized (p  0.006) and utilize Emergency
Department services (p  0.0001). In addition, Medicaid HMO beneficiaries were
20% less likely to have a claim for a Neurologist vist and 50% less likely to be
prescribed disease modifying therapies than commercial enrollees. Long-term ac-
cess tomedical servicesmirrored that observed in the short termwith higher rates
of hospitalization (p  0.006) and emergency department use (p  0.001) and less
access to Neurologist (p  0.001) and disease modifying treatment (p  0.027).
CONCLUSIONS: Opportunities exist to support newly diagnosed MS patients en-
rolled inMedicaidHMOplans. The development and implementation of innovative
managed care strategies will ensure that Medicaid HMO beneficiaries received ac-
cess to specialty care and approved treatments at the same rate as their counter-
parts enrolled in commercial health plans.
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OBJECTIVES: The study examined determinants of prescription drug expenditures
in patients with Multiple Sclerosis (MS) in United States (US). METHODS: Retro-
spective cross-sectional study was conducted using the 2002-2009 Medical Expen-
diture Panel Survey (MEPS) data, a nationally representative data on the commu-
nity dwelling, non-institutionalized US population. The study sample included
patients diagnosed with MS (ICD-9-CM: 340). Weighted descriptive statistics were
performed to estimate the total and prescription drug expenditures. Multiple Or-
dinary Least Square regression analysis within the conceptual framework of An-
derson Behavioral Model was performed to identify factors associated with pre-
scription drug expenditures. The log transformation of the prescription drug
expenditures was carried out to address skewed nature of cost data. RESULTS: An
estimated of 4.1 million patients were diagnosed with MS during 2002-2009. The
total average expenditure for MS patients was $17,619 (95% CI: 16,385-18,913). Of
which 44%was attributable to the prescription drugs cost, i.e. $7760 (95% CI: 7169 –
8350). The linear regression revealed that predisposing (region), enabling (health
insurance coverage) and need (charlson comorbidity score) factors were signifi-
cantly associated with prescription drug expenditures. Patients from the Midwest
region had 65% higher prescription expenditure than the west region patients.
Patients with public insurance had 164% higher prescription expenditures than
uninsured patients. One unit increase in charlson comorbidity score was associ-
ated with 28% higher prescription drug expenditure. CONCLUSIONS: The total
prescription drug expenditures accounted for nearly half of total medical expen-
diture in patients with multiple sclerosis. In addition to need factors, the predis-
posing and enabling factors played an important role in influencing prescription
drug expenditures in patients with multiple sclerosis.
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OBJECTIVES: The objective of this research is to understand emerging value per-
ceptions of novel treatments in Multiple Sclerosis from the perspective of US Man-
aged Care Organization decision makers and prescribing physicians. METHODS:
Explorative primary research interviews (n35) were conducted with a sample of
Managed Care Organization decision makers, practicing neurologists, hospital
pharmacy directors, and specialty pharmacy distribution managers. The sample
was composed of national and regional payers representing various patient popu-
lations with commercial or government-funded coverage. Interviews were con-
ducted from April to June 2011 and consisted of individual one-hour phone inter-
views. Survey questions were focused on identifying payer perceptions of unmet
need in current Multiple Sclerosis (MS) disease management, payer and physician
reactions to the first oral treatment entrant (Gilenya), and projections for changes
in treatment algorithms and benefit design upon availability of additional oral
therapies. Qualitative surveymethods for eliciting stated preferences for formulary
management decisions were used. RESULTS: Payers and physicians described the
unmet need in MS treatment being driven by the absence of optimal disease-
modifying treatments and evidence correlating available treatments to long-term
outcomes. Payers are sensitive to recent price increases in the category and man-
agement practices in MSmay becomemore aggressive in the near-term as compe-
tition for value increases. Payers and physicians anticipate future oral treatments
in development to induce increased in oral drug initiation but do not anticipate
rapid conversion from injectable therapy to oral therapy. CONCLUSIONS: Payers
and prescribers acknowledge oral therapy options for MS as an expansion in treat-
ment options offering more convenient administration. Rising cost of therapy and
evidence of long-term outcome improvement with their utilization remain con-
cerns in supporting the value of these treatments.
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BACKGROUND: US payers often employ a fail-first approach to multiple sclerosis
(MS), imposing multiple steps through therapies as patients relapse, progress and
accumulate disability. However, within the past year, one managed care organiza-
tion has piloted an outcomes-based contract in MS. Tier status and discounts will
be tied to medication adherence, avoidance of relapses and subsequent hospital-
izations. At the same time, the MS therapy pipeline is rapidly evolving, and may
offer opportunities for contracting based on volume, or a portfolio of products for
multiple lines of therapy.OBJECTIVES: To gauge the level of interest among payers
in piloting value-based insurance designs (VBID) for oral and intravenous therapies
in MS. Additionally, to identify characteristics of plans most likely to implement
VBID; and to highlight implications for development of real-world outcomes data
to support innovative contracting. METHODS: Pharmacy and medical directors of
managed care payers will be asked to rate their level of interest in different benefit
designs for oral and intravenous MS therapies. Benefit designs include integrated
medical/pharmacy benefits; open access plans; pathways based on futility rules;
outcomes-based contracting; and risk-sharing tied to avoidance of hospitaliza-
tions. The interview sample will include a mix of plans with different approaches
to use of specialty pharmacy in MS and additional management practices.
RESULTS: Critical success factors for VBID (such as ability to link datasets from
pharmacy and medical claims) will be identified. In addition, specific outcomes
required to design or implement VBID, such as impact of time on ineffective ther-
apy and/ormedication non-adherence, will be prioritized based on payer feedback.
Lastly,metrics for demonstrating return on investment fromVBID inMS, including
PMPM as well as drug budget impact and medical cost offsets, will be elucidated.
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